TGIF: Week’s Stem Cell Headlines, Papers, & Resources

TGIF science dart board

Modified Wikipedia image

What are the latest developments in stem cells and regenerative medicine in this first week of 2017 and right before the end of the past year? Here are some of the headlines and papers that have popped up that seem notable or surprising. Be sure to also check out our stem cell & regenerative medicine meeting hub for 2017.

Alexey’s review of Cell Therapy (including stem cells/regen med) in 2016. Must-read. This links to his part 2 and there is a link to part 1 there. This is on his Cell Trials blog.

A Rapid Pipeline to Model Rare Neurodevelopmental Disorders with Simultaneous CRISPR/Cas9 Gene Editing. Cool system described in Stem Cells article.

Scientists find link between maternal environment and neurodevelopment disorders. More on neurodevelopment. Environment and genetics do a tango in development.

NYSCF and PGP announce availability of unique new stem cell resource for scientific research. More stem cell resources the better.

What happens to rejected papers? Neuroskeptic takes a look. A little off topic, but very interesting.

Stem Cell Research: How Scientists Grew Stomach Tissue In A Lab. Does it get hungry?

How Trump Could Slow Medical Progress. Worries about Trump & biomedical sciences.

Will President Trump restrict embryonic stem cell research funding. More worries on Trump. 

Genetically engineered immune cells melt away deadly brain tumors (from CIRM blog) New approaches to brain tumors are urgently needed. Minor thing — not sure about the use of “melt away” as a metaphor here.

Top 20 Stem Cell Predictions for 2017

stem cell crystal ball

Stem cell crystal ball

Each year I make a list of predictions for the stem cell and regenerative medicine field for the coming new year. Later in this post I list my top 20 stem cell predictions for 2017. In looking at my past predictions I realized this will now be my 7th year doing stem cell/regenerative medicine yearly predictions.

You can see below links to these predictions for past years, which sometimes seems rather far removed from today and in other cases strike me as strangely apropos of our times.

What will 2017 bring? Below are my top 20 predictions in no particular order except starting with a few hopeful visions for the coming year.

Continue reading

Trump Has FDA in Crosshairs: Impact on Stem Cell Oversight?

fda-trump-healthcareWill Trump trump the FDA?

Our President-elect recently released his health care policy agenda and it looks like the FDA is a target in terms of reducing oversight. Over at the Washington Post, Carolyn Johnson has a nice article on this development.

One point in the agenda in particular has caught people’s attention as potentially the key indicator of what is to come for regulatory oversight of biomedical products:

  • “Reform the Food and Drug Administration, to put greater focus on the need of patients for new and innovative medical products”

This one sentence says a great deal in terms of signaling that Trump wants dramatically less oversight or at least that’s how “reform” is being interpreted.

For those of us in the stem cell field this sentence from Trump sounds very reminiscent of language from proponents of reduced regulation and even stem cell clinics, who say they are just in it for the patients but keep keeping racking up profits.

This signal from Trump does not bode well for stem cell and regenerative medicine oversight in the coming years, but we’ll have to stay tuned to see how this develops.